Recombinant mouse cytomegalovirus expressing a ligand for the NKG2D receptor is attenuated and has improved vaccine properties. - Test2 - elhamkhani - TriplyDB

Recombinant mouse cytomegalovirus expressing a ligand for the NKG2D receptor is attenuated and has improved vaccine properties.

Recombinant mouse cytomegalovirus expressing a ligand for the NKG2D receptor is attenuated and has improved vaccine properties.

http://www.wikidata.org/entity/Q34360228

about

Viral Evasion of Natural Killer Cell Activation Immunobiology of congenital cytomegalovirus infection of the central nervous system—the murine cytomegalovirus model Boosting vaccine efficacy the natural (killer) way Multiparametric analysis of host response to murine cytomegalovirus in MHC class I-disparate mice reveals primacy of Dk-licensed Ly49G2+ NK cells in viral control.Deciphering the role of DC subsets in MCMV infection to better understand immune protection against viral infections Dok1 and Dok2 proteins regulate natural killer cell development and function.Can we build it better? Using BAC genetics to engineer more effective cytomegalovirus vaccines.IL-10 suppression of NK/DC crosstalk leads to poor priming of MCMV-specific CD4 T cells and prolonged MCMV persistence.Modulation of CD112 by the alphaherpesvirus gD protein suppresses DNAM-1-dependent NK cell-mediated lysis of infected cells.Transmission of murine cytomegalovirus in breast milk: a model of natural infection in neonates NK cells: immune cross-talk and therapeutic implications.The NK cell response to mouse cytomegalovirus infection affects the level and kinetics of the early CD8(+) T-cell response.Siglec-H protects from virus-triggered severe systemic autoimmunity.Natural Killer Cell Evasion Is Essential for Infection by Rhesus Cytomegalovirus Cytomegalovirus Reinfections Stimulate CD8 T-Memory Inflation Activation of Innate and Adaptive Immunity by a Recombinant Human Cytomegalovirus Strain Expressing an NKG2D Ligand An attenuated cytomegalovirus vaccine with a deletion of a viral chemokine gene is protective against congenital CMV transmission in a guinea pig model Superior induction and maintenance of protective CD8 T cells in mice infected with mouse cytomegalovirus vector expressing RAE-1γ.Developing a Vaccine against Congenital Cytomegalovirus (CMV) Infection: What Have We Learned from Animal Models? Where Should We Go Next?The p36 isoform of murine cytomegalovirus m152 protein suffices for mediating innate and adaptive immune evasion.All is fair in virus-host interactions: NK cells and cytomegalovirus.Manipulation of NKG2D ligands by cytomegaloviruses: impact on innate and adaptive immune response.Innate immunity regulates adaptive immune response: lessons learned from studying the interplay between NK and CD8+ T cells during MCMV infection The evolutionary arms race between NK cells and viruses: who gets the short end of the stick?Cytomegalovirus vaccine: phase II clinical trial results.MCMV avoidance of recognition and control by NK cells.Cytomegalovirus vector expressing RAE-1γ induces enhanced anti-tumor capacity of murine CD8+ T cells.Cutting Edge: NKG2D Signaling Enhances NK Cell Responses but Alone Is Insufficient To Drive Expansion during Mouse Cytomegalovirus Infection.Natural killer group 2D and CD28 receptors differentially activate mammalian/mechanistic target of rapamycin to alter murine effector CD8+ T-cell differentiation.The specific NK cell response in concert with perforin prevents CD8(+) T cell-mediated immunopathology after mouse cytomegalovirus infection.Could therapeutic vaccination of cytomegalovirus-seropositive persons prevent reinfection and congenital virus transmission?Is HCMV vaccine an unmet need? The state of art of vaccine development.Immune responses to congenital cytomegalovirus infection.CMV and natural killer cells: shaping the response to vaccination.Herpesvirus Evasion of Natural Killer Cells.Murine CMV Expressing the High Affinity NKG2D Ligand MULT-1: A Model for the Development of Cytomegalovirus-Based Vaccines.Maternal Immunity and the Natural History of Congenital Human Cytomegalovirus Infection

P2860

Q26748421-F960B473-CF48-4554-BAC2-1D07C47D25E2 Q27026924-3FE970C3-45FC-47FF-A204-2784AE9B4BE2 Q28084474-6C36E9C9-124A-4EAF-AD5E-BDBFDCC73824 Q30409829-7FBF83D1-E652-4960-BD28-BBC999BAB71C Q33965560-7594819A-A634-4A47-9DAD-2E89A1A36874 Q34332499-40C3F683-F217-45F8-B092-A986C6F0BFC3 Q34360247-0C5FCCE4-54A3-4267-9761-DBD3CC5DF10F Q34372333-BD0D28D2-EB99-493C-AF80-1BC2551C7346 Q34526520-13026552-6B73-4F13-9F9A-BFDAB8850E7A Q35076650-9AF0C7BD-8EE4-40C3-A481-93F0ACE716EC Q35591444-97E18994-5B6E-4EC2-8079-94833F213E23 Q35826529-958F8CC1-6C0A-434E-9BF4-EA6BE4D76582 Q36067728-C1B85396-4042-4779-8C38-370A27DD46CD Q36118554-89ECB30D-4258-4259-872E-3A969E06DEF0 Q36199934-3D9B470A-9EFD-4DE2-997E-43F959D85049 Q36210368-4C3A0B81-8156-44A2-BEC3-7F8B5B92742A Q37127280-2F0518BB-0024-4644-A37F-3D72B54EDDE1 Q37236631-B5134D94-D218-47E9-8E9D-524C09DEBF51 Q37574334-6ED2F8DE-C85F-4047-AE10-98304631F600 Q37666790-928FAA1B-2A32-49B1-8199-83049393DDFE Q37919670-58C2E7A7-8C7C-4652-A26F-F56328FB9A2D Q38008345-24C841EF-A060-4C95-9A1F-F3D1C8821802 Q38042327-7CD2263F-BBCD-4B42-B62A-A48BCBA19562 Q38084615-435A2F6A-A58C-4109-BF63-5F3BBBAE3FB6 Q38166861-76F4E64B-3102-4B05-8AB9-0871E0F1BDFD Q38241668-293C55E1-F7F9-4C54-827B-61B88076F40D Q38726244-C89B2FE3-656A-496A-9D6F-E917D2D02A17 Q40100662-82C2A84C-BC96-4E46-ACDB-5C1D43477DAC Q40217706-FF526AFA-5F14-4E4F-87C4-FEFF230F48F8 Q41384086-2673D9D1-98F7-4D14-BAAB-D1D61E48F286 Q42735574-E8B11F8D-F976-4634-834D-313571362D75 Q43467283-18526ADA-0074-4BA9-8B35-44F2C009D0E4 Q47559622-91DC7B1F-321B-4D8C-B15C-54C902BB41D6 Q48273032-2FB4AF68-0221-4D86-B171-BE93364F10DB Q54255834-80E681D0-8C70-4DC9-8B8A-B80A05B30ED5 Q55408876-93ED6C22-B843-442C-BDD3-F30986F5E3F5 Q58801058-FF48AF03-C008-4415-B37C-43FD65449444

P2860

Recombinant mouse cytomegalovirus expressing a ligand for the NKG2D receptor is attenuated and has improved vaccine properties.

http://www.wikidata.org/entity/Q34360228

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Recombinant mouse cytomegalovi ...... s improved vaccine properties.

@ast

Recombinant mouse cytomegalovi ...... s improved vaccine properties.

@en

Recombinant mouse cytomegalovi ...... s improved vaccine properties.

@nl

type

label

Recombinant mouse cytomegalovi ...... s improved vaccine properties.

@ast

Recombinant mouse cytomegalovi ...... s improved vaccine properties.

@en

Recombinant mouse cytomegalovi ...... s improved vaccine properties.

@nl

prefLabel

Recombinant mouse cytomegalovi ...... s improved vaccine properties.

@ast

Recombinant mouse cytomegalovi ...... s improved vaccine properties.

@en

Recombinant mouse cytomegalovi ...... s improved vaccine properties.

@nl

P1433

Q34360228-9C02AE5B-1BDA-49CC-882D-668948CD0390

P1476

Q34360228-EA28F981-51F3-46CA-A231-9EDA7E6453F5

P2093

Q34360228-09668863-B099-4D76-B64A-24C7458A61E4

Q34360228-54FF0E71-A24B-4EB3-828A-EF763D886F66

Q34360228-61CECEC3-5347-46CC-9701-C0A197AA55FB

Q34360228-6F6767EE-FF8E-4781-8B45-1C8D24376AAA

Q34360228-8D5115B5-5096-4E5E-B500-23E04B026C61

Q34360228-95971C56-42B9-471C-8244-08F97ABC90C1

Q34360228-B031C499-B468-4B60-833C-AD798500A6BE

Q34360228-C2417170-5EDF-4811-AA82-C56C0FC9206F

P2860

Q34360228-00D14922-8F82-48BD-85CC-169D522EC480

Q34360228-03ED2F0F-B828-46CA-8F1F-5193873CC200

Q34360228-0766CBD6-9BB9-4A3A-9B15-EB92D5F8BDC8

Q34360228-0A235833-E90B-4437-B2AC-484D3490CFBB

Q34360228-0FDEE3BC-A7EB-40DE-B486-5C7C249EB1E5

Q34360228-1615E8E4-975B-4862-B9F2-CE74191622FF

Q34360228-198A55ED-E0BD-4E66-8EA6-269E9D94E8BA

Q34360228-19F05C12-5C8C-4CA6-9A51-D6B457335085

Q34360228-1B0781C7-10D3-4BBA-9347-D8E16A8C239B

Q34360228-1B49A316-4A13-4E2A-AEE5-CFA8E9DCD2D0

P304

Q34360228-DC5AE2C3-629C-441E-850E-905C52817977

P31

Q34360228-06D16760-F8F8-41E8-BA38-A90C0240EE37

P356

Q34360228-ADEC9FC1-590D-4B0C-9C0E-602B286D5010

P407

Q34360228-C282E3A7-EF16-437A-A835-0DB7B6F518E0

P433

Q34360228-7E4C6683-5C0E-4E5E-A628-EB986C91A071

P478

Q34360228-509C292E-3A67-4022-904A-7F4C1EA0D2AB

P50

Q34360228-00AE6187-942B-4425-BDE3-51A221FA5FA9

Q34360228-03DAB3A7-DF7F-4209-A4AE-0F75CDD60107

Q34360228-1949F12B-5642-4D10-A73A-29E16C18BFDF

Q34360228-2AAA29F8-654C-476E-AFC5-EC6CB43E25FC

Q34360228-431ACDE0-4EA8-4475-BD95-B891CCD94904

Q34360228-8660AEC5-9309-4D08-B510-C19BDF1D4465

Q34360228-924BA901-936A-4DC9-B175-DC97A19AC844

P577

Q34360228-51859165-C0D3-423C-B736-7D3A06EC7367

P698

Q34360228-3F435974-D029-4602-98FD-B3D4A9456DF5

P921

Q34360228-3543C0C4-6E8C-4CD0-AEA9-30F9CC60D14A

Q34360228-861C8FD7-71E6-464A-B6BA-1A7319CB9CB8

Q34360228-B38A0B2B-AAE8-4FB5-9DA1-EF648A7BC021

P932

Q34360228-729A0534-2D77-458F-BCC9-C1819D3D0183

P356

P1433

Journal of Clinical Investigation

P1476

Recombinant mouse cytomegalovi ...... as improved vaccine properties

@en

P2093

Ana Ciković

http://www.w3.org/2001/XMLSchema#string

Andreas Busche

http://www.w3.org/2001/XMLSchema#string

Irena Slavuljica

http://www.w3.org/2001/XMLSchema#string

Maja Mitrović

http://www.w3.org/2001/XMLSchema#string

Marina Babić

http://www.w3.org/2001/XMLSchema#string

Ulrich Koszinowski

http://www.w3.org/2001/XMLSchema#string

Vanda Juranić Lisnić

http://www.w3.org/2001/XMLSchema#string

William J Britt

http://www.w3.org/2001/XMLSchema#string

P2860

Cloning and mutagenesis of a herpesvirus genome as an infectious bacterial artificial chromosome

Vaccine prevention of maternal cytomegalovirus infection

Natural killer cells promote early CD8 T cell responses against cytomegalovirus

A new logic for DNA engineering using recombination in Escherichia coli

Quantitative measurement of infectious murine cytomegalovirus genomes in real-time PCR.

Symptomatic congenital cytomegalovirus infection: neonatal morbidity and mortality.

Cross-presentation of a spread-defective MCMV is sufficient to prime the majority of virus-specific CD8+ T cells.

In vivo replication, latency, and immunogenicity of murine cytomegalovirus mutants with deletions in the M83 and M84 genes, the putative homologs of human cytomegalovirus pp65 (UL83).

Cytomegalovirus vaccine development

Modulation of natural killer cells by human cytomegalovirus.

P304

4532-4545

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI43961

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

120

http://www.w3.org/2001/XMLSchema#string

P50

Martin Messerle

Astrid Krmpotic

Ester Pernjak Pugel

Elitza P Markova

Iva Gašparović

Durđica Cekinović

P577

2010-11-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21099111

http://www.w3.org/2001/XMLSchema#string

P921

attenuated vaccine

maternal health

Cytomegalovirus

P932

2993599

http://www.w3.org/2001/XMLSchema#string